Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Cited by (2,225)

Items 2,201–2,225 of 2,225

1. How cystic fibrosis modulator therapy could transform Pseudomonas aeruginosa epidemiology
   James Gurney, Morgana Letizia, Sheyda Azimi, Stephen P. Diggle · 2026 · Microbiology
2. Genetic hepatocellular cholestasis: an update
   Antoine Gardin, William Pouillot, Marion Almes, Charlotte Mussini, Emmanuel M. Gonzales, Emmanuel Jacquemin · 2026 · Clinics and Research in Hepatology and Gastroenterology
3. Cardiovascular Manifestations of Cystic Fibrosis
   Krishan Gopal Garg, Ankit Agrawal, Ahmad Mustafa, Mohab Elnashar, Gunner Gilbert, Akiva Rosenzveig, Arnav Lakkimsetti, Elio Haroun, Aro Daniela Arockiam, Karim Hoyek et al. · 2026 · Journal of Clinical Medicine
4. Model-informed dose reduction of elexacaftor/tezacaftor/ivacaftor therapy in adult people with cystic fibrosis: A simulation study
   Tom C. Zwart, Syendon B C Baromeo, Inez Bronsveld, Harry G.M. Heijerman, Erik B. Wilms, Renske van der Meer · 2026 · Journal of Cystic Fibrosis
5. From historical dosing to precision dosing: Modernising tobramycin monitoring in people with cystic fibrosis
   Ellie Johnson, Michael Williams, Daniel Henderson, Timothy Riddles, David W. Reid, D. Smith, Andrew Burke, Ieuan Evans · 2026 · European Journal of Clinical Pharmacology
6. Non-eligibility for highly effective modulator therapy with elexacaftor/tezacaftor/ivacaftor in cystic fibrosis: What about Portugal?
   Elsa C. FRAGOSO, Pilar Azevedo, L. Pereira, Telma Barbosa, Ana Lúcia Cardoso, Célia Cruz, Adelina A. Amorim, Inês Azevedo, Leonor Mendonça Almeida, Susana Castanhinha et al. · 2026 · Pulmonology
7. Changes in Gastrointestinal Symptoms Among Children With Cystic Fibrosis During 12 Months of Elexacaftor/Tezacaftor/Ivacaftor Therapy: A Swedish Multicentre Study
   Marcus Svedberg, Ellen Karlge Nilsson, Per Ekman, Henrik Imberg · 2026 · Acta Paediatrica
8. Hyperpolarized Xenon 129 MRI to Evaluate Regional Gas-Exchange Abnormalities in Cystic Fibrosis Lung Disease
   Stephanie A. Soderlund, Ismail Bilal Masokano, Matthew M. Willmering, Abdullah S. Bdaiwi, Riaz Hussain, Elizabeth L. Kramer, Laura L. Walkup, Zackary I. Cleveland · 2026 · Radiology Cardiothoracic Imaging
9. Respiratory health in cystic fibrosis: much done, more to do!
   Sharon E. Weinberg, Peter James Barry · 2026 · Thorax
10. Longitudinal changes in bone mineral density among adults with cystic fibrosis: a systematic review and meta-analysis
    Arunan Selvarajah, Alexandra E. Dittrich, Viethushaa Mohandas, Jenna R. Sykes, Reem Jad, Lisa J. Strug, Gillian L. Booth, Jane A. E. Batt, Anne L. Stephenson · 2026 · Osteoporosis International
11. BindingDB Entry 50013315: Novel bacterial topoisomerase inhibitors derived from isomannide.
    BindingDB · 2022 · UC San Diego
12. BindingDB Entry 50021919: Synthesis and Biological Evaluation of Pyrazole-Pyrimidones as a New Class of Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
    BindingDB · 2025 · UC San Diego
13. BindingDB Entry 50016722: Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
    BindingDB · 2023 · UC San Diego
14. BindingDB Entry 50016395: Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis.
    BindingDB · 2023 · UC San Diego
15. BindingDB Entry 50023429: Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.
    BindingDB · 2026 · UC San Diego
16. BindingDB Entry 50018239: Synthetic Approaches to the New Drugs Approved during 2019.
    BindingDB · 2024 · UC San Diego
17. BindingDB Entry 50016105: Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
    BindingDB · 2023 · UC San Diego
18. BindingDB Entry 50012286: New drug approvals for 2019: Synthesis and clinical applications.
    BindingDB · 2022 · UC San Diego
19. BindingDB Entry 50021321: Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms.
    BindingDB · 2025 · UC San Diego
20. Plethysmography as a Complementary Tool for Monitoring Response to CFTR Modulator Therapy in Children with Cystic Fibrosis: A Real-World Study
    Magdalena Postek, Katarzyna Walicka‐Serzysko, Urszula Borawska-Kowalczyk, Justyna Milczewska, Katarzyna Zybert, Anna Wołkowicz, Łukasz Woźniacki, Dorota Sands · 2026 · Journal of Clinical Medicine
21. Cystic fibrosis
    Felix A. Ratjen, Natalia S. Escobar · 2026 · Elsevier eBooks
22. ERAD-Mediated Functional Knockout: Degradation of Potentially Active Mutant Proteins in Inherited Diseases
    Julia V. Sopova, U. A. Terenteva, Е. И. Леонова · 2026 · Cell and Tissue Biology
23. Gestational weight gain and health-related quality of life during pregnancy and the early postpartum period in women with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor
    Nele-Kristin Vagt-Detering, Marleen Picker, Clarissa Thoms, Svenja Straßburg, Christian Taube, Gerhard Weinreich, Julija Judickiene, Maria Panagi, Matthias Welsner, Sivagurunathan Sutharsan et al. · 2026 · Respiratory Medicine
24. An analysis of cystic fibrosis transmembrane conductance regulator gene variants in the Cystic Fibrosis Registry of Türkiye
    Burcu Çapraz Yavuz, Ali Samet Kara, Didem Dayangac Erden, Velat Şen, Hadice Selimoğlu Şen, Berrak Öztosun, Cigdem Korkmaz, Ayse Ayzit Kilinc, Suat Savaş, Fatih Ercan et al. · 2026 · European Journal of Pediatrics
25. Offering prenatal CFTR modulators to prevent cystic fibrosis-related organ damage in utero
    Carrie Saleeb, Whitney D Gore, M Gajo, Maria Del Carmen Reyes, Stephanie Lopez, Jeeyeon Kim, Linda Marie Randolph, Ramen H. Chmait, Lawrence D. Platt, David A Miller et al. · 2026 · American Journal of Obstetrics & Gynecology MFM